According to a filing made in the Republic of Korea, Samsung Bioepis has disclosed that Merck has terminated the companies' development and commercialization agreement for a follow-on insulin glargine product referencing Sanofi’s Lantus.
According to a filing made in the Republic of Korea, Samsung Bioepis has disclosed that Merck has terminated the companies' development and commercialization agreement for a follow-on insulin glargine product referencing Sanofi’s Lantus.
Despite tentative FDA approval received in July 2017, Merck and Samsung have faced significant challenges in bringing the follow-on biologic, Lusduna Nexvue, to market in the United States.
One hurdle, patent infringement litigation brought by reference product developer Sanofi, was ongoing, and triggered an automatic stay on the FDA’s final approval of up to 30 months.
Merck concluded to end the partnership after assessing the current and future market for the product, including pricing and the product’s cost, before reaching its decision. In ending the partnership, Merck paid Samsung $155 million to cover investments made thus far in the product, plus interest, reported FiercePharma. However, its partnership with Samsung on other biosimilars in oncology and immunology remain unchanged.
Drug developer Mylan, in a partnership with Biocon, is having similar troubles with its follow-on insulin referenced on Lantus. The product, which is already approved in Europe and sold under the name Semglee, is currently undergoing its own patent lawsuit from Sanofi. In the 70-page lawsuit filed in October 2017, Sanofi alleged that Mylan is infringing on 18 patents and asked a federal court in New Jersey to intervene in the launch efforts.
The lawsuit, however, is not the only challenge Mylan has faced in bringing its follow-on insulin to market, as it received a Complete Response Letter (CRL) from the FDA in June, citing production problems at the Malaysia plant responsible for producing the product.
Competing against reference Lantus in the follow-on insulin market already is Boehringer Ingelheim’s Basaglar, the first follow-on insulin glargine to earn FDA approval.
The Trump Administration’s Drug Price Actions and Why US Prices Are Already Sky-High
May 17th 2025While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more complex web of development costs, profit incentives, and absent price controls—raising the question of whether any single policy, including potential drug tariffs, can truly untangle it.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.